



FORM PTO-1449/A and B (Modification) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/622,076		ATTY. DOCKET NO.: C0989.70054US00	
				FILING DATE: July 17, 2003		CONFIRMATION NO.: 1842	
				APPLICANT: Rudolf Gilmanshin			
				GROUP ART UNIT: 1724		EXAMINER: Not Yet Assigned	
Sheet	1	of	1				

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
AB		6,355,420	B1	Chan	03-12-2002

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	

EXAMINER /Angela Bertagna/	DATE CONSIDERED 05/17/2006
-----------------------------------	-----------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

DEC 8 2005
FORM PTO-1449/A and (modified PTO/SB/08)
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 3

APPLICATION NO.: 10/622,076

ATTY. DOCKET NO.: C0989.70054US00

FILING DATE: July 17, 2003

CONFIRMATION NO.: 1842

APPLICANT: Gilmanshin et al.

GROUP ART UNIT: 1637

EXAMINER: Angela Marie Bertagna

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
AB	A2	4,737,454		Dattagupta et al.	04-12-1988
	A3	4,873,187		Taub et al.	10-10-1989
	A4	4,959,309		Dattagupta et al.	09-25-1990
	A5	5,525,465		Haralambidis et al.	06-11-1996
	A6	5,629,178		Demers	05-13-1997
	A7	5,955,590		Levina et al.	09-21-1999
	A8	6,110,676		Coull et al.	08-29-2000
	A9	6,165,720		Felgner et al.	12-26-2000
	A10	6,197,513	B1	Coull et al.	03-06-2001
	A11	6,210,896	B1	Chan	04-03-2001
	A12	6,225,063	B1	Khvorova et al.	05-01-2001
	A13	6,263,286	B1	Gilmanshin et al.	06-17-2001
	A14	6,280,946	B2	Hyldig-Nielsen et al.	08-28-2001
	A15	6,287,772	B1	Stefano et al.	09-11-2001
	A16	6,312,894	B1	Hedgpeth et al.	11-06-2001
	A17	6,403,311	B1	Chan	06-11-2002
	A18	6,696,022	B1	Chan et al.	02-24-2004
	A19	6,762,059	B2	Chan et al.	07-13-2004
	A20	6,772,070	B2	Gilmanshin et al.	08-16-2004
	A21	6,790,671	B1	Austin et al.	09-14-2004
	A22	6,927,065		Chan et al.	08-09-2005
	A23	2002-0110818	A1	Chan	08-15-2002
	A24	2002-0119455	A1	Chan	08-29-2002
	A25	2002-0187508	A1	Wong	12-12-2002
	A26	2002-0197639	A1	Shia et al.	12-26-2002
	A27	2003-0059822	A1	Chan et al.	03-27-2003
	A28	2003-0215864	A1	Gilmanshin et al.	11-20-2003
	A29	2003-0235854	A1	Chan	12-25-2003
	A30	2004-0009612	A1	Zhao et al.	01-15-2004
	A31	2004-0166025	A1	Chan et al.	08-26-2004
	A32	2004-0214211	A1	Gilmanshin et al.	10-28-2004
AB	A33	2004-0235014	A1	Nadel et al.	11-25-2004

EXAMINER:

/Angela Bertagna/

DATE CONSIDERED:

05/17/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/622,076		ATTY. DOCKET NO.: C0989.70054US00	
				FILING DATE: July 17, 2003		CONFIRMATION NO.: 1842	
				APPLICANT: Gilmanshin et al.			
				GROUP ART UNIT: 1637		EXAMINER: Angela Marie Bertagna	
Sheet	2	of	3				

AB	A34	2005-0042665	A1	Gilmanshin	02-24-2005
	A35	2005-0112595	A1	Zhao et al.	05-26-2005
	A36	2005-0112606	A1	Fuchs et al.	05-26-2005
	A37	2005-0112620	A1	Chan	05-26-2005
	A38	2005-0112671	A1	Maletta et al	05-26-2005
	A39	2005-0123944	A1	Neely et al.	06-09-2005
	A40	2005-0123974	A1	Gilmanshin et al.	06-09-2005
	A41	2005-0142595	A1	Maletta et al.	06-30-2005
	A42	2005-0153354	A1	Gilmanshin et al.	07-04-2005
	A43	2005-0196790	A1	Rooke et al.	09-08-2005
AB	A44	2005-0221408	A1	Nalefski et al.	10-06-2005

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
AB	B1	WO	98/35012	A2	U.S. Genomics, Inc.	08-13-1998	
AB	B2	WO	00/09757	A1	U.S. Genomics, Inc.	02-24-2000	
AB	B3	WO	01/13088	A1	U.S. Genomics, Inc.	02-22-2001	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
AB	C1	ALAHARI et al., Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol. 1996 Oct;50(4):808-19. Abstract Only.	
	C2	BRAASCH et al., Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Biol. 2001 Jan;8(1):1-7. Abstract Only.	
	C3	BUNNELL et al., Targeted delivery of antisense oligonucleotides by molecular conjugates. Somat Cell Mol Genet. 1992 Nov;18(6):559-69. Abstract Only.	
	C4	GRIGORIEV et al., Inhibition of gene expression by triple helix-directed DNA cross-linking at specific sites. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3501-5.	
AB	C5	KOSHKIN et al., A simplified and efficient route to 2'-O, 4'-C-methylene-linked bicyclic ribonucleosides (locked nucleic acid). J Org Chem. 2001 Dec 14;66(25):8504-12. Abstract Only.	

EXAMINER: /Angela Bertagna/	DATE CONSIDERED: 05/17/2006
------------------------------------	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/622,076		ATTY. DOCKET NO.: C0989.70054US00	
				FILING DATE: July 17, 2003		CONFIRMATION NO.: 1842	
				APPLICANT: Gilmanshin et al.			
				GROUP ART UNIT: 1637		EXAMINER: Angela Marie Bertagna	
Sheet	3	of	3				

AB	C6	LIANG et al., Targeted delivery of plasmid DNA to myogenic cells via transferrin-conjugated peptide nucleic acid. Mol Ther. 2000 Mar;1(3):236-43. Abstract Only.	
	C7	MODRICH et al., EcoRI endonuclease. Physical and catalytic properties of the homogenous enzyme. J Biol Chem. 1976 Oct 10;251(19):5866-74.	
	C8	NORTON et al., Targeting peptide nucleic acid-protein conjugates to structural features within duplex DNA. Bioorg Med Chem. 1995 Apr;3(4):437-45. Abstract Only.	
	C9	ORUM et al., Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development. Curr Opin Mol Ther. 2001 Jun;3(3):239-43. Abstract Only.	
	C10	PARDRIDGE et al., Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5592-6.	
	C11	PETERSEN et al., The conformations of locked nucleic acids (LNA). J Mol Recognit. 2000 Jan-Feb;13(1):44-53. Abstract Only.	
	C12	RAJUR et al., Covalent protein-oligonucleotide conjugates for efficient delivery of antisense molecules. Bioconjug Chem. 1997 Nov-Dec;8(6):935-40. Abstract Only.	
	C13	SAM et al., Catalytic roles of divalent metal ions in phosphoryl transfer by EcoRV endonuclease. Biochemistry. 1999 May 18;38(20):6576-86. Abstract Only.	
	C14	TAYLOR et al., Probing specific sequences on single DNA molecules with bioconjugated fluorescent nanoparticles. Anal Chem. 2000 May 1;72(9):1979-86.	
↓	C15	WAGNER et al., Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc Natl Acad Sci U S A. 1990 May;87(9):3410-4.	
AB	C16	ZENKE et al., Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoietic cells. Proc Natl Acad Sci U S A. 1990 May;87(10):3655-9.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	/Angela Bertagna/	DATE CONSIDERED:	05/17/2006
-----------	-------------------	------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.